^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)

    i
    Other names: TACC1, Transforming Acidic Coiled-Coil Containing Protein 1, Transforming Acidic Coiled-Coil-Containing Protein 1, Gastric Cancer Antigen Ga55, Taxin-1, Transforming, Acidic Coiled-Coil Containing Protein 1, KIAA1103, Ga55
    8d
    Integrative bioinformatics identifies NSCLC biomarkers associated with LPS metabolism and circadian disruption. (PubMed, Transl Oncol)
    This study identifies a novel gene signature linked to LPS metabolism and circadian disruption in NSCLC, with validated diagnostic utility and implications for tumor immune regulation. CACNA2D2 emerges as a key tumor suppressor, offering insights for early detection and targeted therapy development.
    Journal
    |
    TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1) • TSLP (Thymic Stromal Lymphopoietin)
    2ms
    Activated RARα counteracts the effects of TACC1v25 on the differentiation and invasion of head and neck squamous cell carcinoma. (PubMed, Transl Cancer Res)
    It is possible that ATRA induces conformational changes and/or promotes nuclear translocation of RARα, which in turn reduces its interaction with TACC1v25 and modulates the downstream transcriptional effects. This may provide new ideas for treating HNSCCs.
    Journal
    |
    RARA (Retinoic Acid Receptor Alpha) • VIM (Vimentin) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    12ms
    Spontaneous regression of epileptogenic pilocytic astrocytoma with FGFR1-TACC1 fusion. (PubMed, Childs Nerv Syst)
    This case suggests that FGFR1-TACC1 fusion may be linked to spontaneous regression of PA, even in the absence of NF1. Surgical intervention may remain necessary in cases of epilepsy associated with PA, regardless of tumor regression.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • NF1 (Neurofibromin 1) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    1year
    Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk. (PubMed, Prostate)
    The identified blood-based candidate susceptibility genes provide further insights into the genetic basis of PCa risk.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • LMNA (Lamin A/C) • EP300 (E1A binding protein p300) • PIK3C2B (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta) • SECTM1 (Secreted and transmembrane 1) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1) • TRAF1 (TNF Receptor Associated Factor 1) • H2AZ2 (H2A.Z Variant Histone 2) • MAPK3 (Mitogen-Activated Protein Kinase 3) • NKX3-1 (NK3 homeobox 1)
    over1year
    Recurrent symptomatic intracranial hemorrhage in high-grade astrocytoma with piloid features: illustrative case. (PubMed, J Neurosurg Case Lessons)
    Although recurrent symptomatic intracranial hemorrhages are rare in HGAP, enhancing lesions on magnetic resonance imaging suggest the need for resection to obtain tissue for molecular diagnosis and guide adjuvant treatment strategies. https://thejns.org/doi/10.3171/CASE24395.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    |
    CDKN2A deletion • FGFR1 fusion • FGFR1-TACC1 fusion
    over1year
    CD34-positive spindle cell tumour with FGFR1::TACC1 fusion: entity of uncertain behaviour (ECP 2024)
    In this particular case, the immunohistochemical and molecular results support a diagnosis of a fibroblastic/myofibroblastic tumour of uncertain behaviour. Notably, there have been no reported cases in the literature of a soft tissue tumour harboring FGFR1::TACC1 fusion as a primary occurrence in this anatomical location. The patient remains in good health without any evidence of disease recurrence at the 5-month follow-up post-surgical intervention.
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • MDM2 (E3 ubiquitin protein ligase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD34 (CD34 molecule) • MME (Membrane Metalloendopeptidase) • COL1A1 (Collagen Type I Alpha 1 Chain) • NTRK (Neurotrophic receptor tyrosine kinase) • STAT6 (Signal transducer and activator of transcription 6) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    |
    MDM2 amplification • FGFR1 fusion • CD34 positive
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    over1year
    Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies. (PubMed, JCO Precis Oncol)
    mLGGs of early childhood are often aggressive tumors, resistant to CT, and frequently require alternative treatment. The majority of patients harbor druggable molecular targets and respond to molecular TT.
    Journal
    |
    BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1) • KIAA1549 • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    |
    Mekinist (trametinib)
    over1year
    Histopathological and Molecular Heterogeneity of Tumors classifying as Dysembryoplastic Neuroepithelial Tumour (DNT) by DNA Methylation (AANP 2024)
    However, our data suggest that brain tumor lesions classifying as DNT by DNA methylation with low score represent a diverse group. Furthermore, some FCD can classify as DNT, albeit with low calibrated score and require close correlation.
    Epigenetic controller
    |
    BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ETV1 (ETS Variant Transcription Factor 1) • PRKCA (Protein Kinase C Alpha) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1) • TNS3 (Tensin 3)
    |
    NYU Langone Genome PACT assay
    almost2years
    FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma. (PubMed, Genes Chromosomes Cancer)
    However, it remains unclear if FGFR1 fusions define a novel subset of RMS or alternatively, whether this alteration can sporadically drive the pathogenesis of known RMS subtypes, such as ERMS. Additional larger series with integrated genomic and epigenetic datasets are needed for better subclassification, as the resulting oncogenic kinase activation underscores the potential for targeted therapy.
    Journal
    |
    TP53 (Tumor protein P53) • FGFR1 (Fibroblast growth factor receptor 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • DICER1 (Dicer 1 Ribonuclease III) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1) • NCOA2 (Nuclear Receptor Coactivator 2) • PAX3 (Paired Box 3)
    |
    TP53 mutation • FGFR1 overexpression • TET2 mutation • FGFR1 fusion
    2years
    Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients. (PubMed, J Clin Pathol)
    The study provided insights into MAPK-altered gliomas in Kuwait highlighting the differences among paediatric and adult patients and providing a framework for planning therapeutic polices.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NF1 (Neurofibromin 1) • KIAA1549 • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • TACC1 (Transforming Acidic Coiled-Coil Containing Protein 1)
    |
    BRAF V600E • NTRK2 fusion • NF1 mutation • ROS1 fusion • KIAA1549-BRAF fusion • BRAF fusion • FGFR1 fusion • BRAF amplification